Leaders of the US Food and Drug Administration’s Oncology Center of Excellence say sponsors can more readily obtain evidence to confirm or refute the clinical benefit of drugs granted accelerated approval by conducting a randomized trial prior to obtaining approval.
In a New England Journal of Medicine perspective piece published on 21 September, they note that oncology drug sponsors...






